TRIGGIANI, Massimo
 Distribuzione geografica
Continente #
AS - Asia 11.871
NA - Nord America 11.336
EU - Europa 2.726
SA - Sud America 1.110
AF - Africa 135
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 5
Totale 27.200
Nazione #
US - Stati Uniti d'America 11.173
HK - Hong Kong 6.848
SG - Singapore 2.179
CN - Cina 1.018
BR - Brasile 831
VN - Vietnam 817
IT - Italia 575
UA - Ucraina 510
RU - Federazione Russa 356
DE - Germania 334
TR - Turchia 255
FR - Francia 219
IE - Irlanda 213
KR - Corea 194
AR - Argentina 132
FI - Finlandia 125
BD - Bangladesh 124
IN - India 98
GB - Regno Unito 94
SE - Svezia 87
CA - Canada 72
IQ - Iraq 66
MX - Messico 44
ES - Italia 41
EC - Ecuador 38
ID - Indonesia 38
CO - Colombia 37
ZA - Sudafrica 36
AT - Austria 34
JP - Giappone 34
PK - Pakistan 33
PL - Polonia 26
NL - Olanda 24
SA - Arabia Saudita 22
MA - Marocco 20
PY - Paraguay 18
VE - Venezuela 18
AE - Emirati Arabi Uniti 17
UZ - Uzbekistan 16
JO - Giordania 14
MY - Malesia 14
CZ - Repubblica Ceca 13
KE - Kenya 13
CL - Cile 12
PE - Perù 12
EG - Egitto 10
NZ - Nuova Zelanda 10
PH - Filippine 10
CR - Costa Rica 9
IL - Israele 9
JM - Giamaica 9
ET - Etiopia 8
KZ - Kazakistan 8
LT - Lituania 8
AL - Albania 7
AU - Australia 7
CH - Svizzera 7
DZ - Algeria 7
NP - Nepal 7
PA - Panama 7
SY - Repubblica araba siriana 7
TN - Tunisia 7
UY - Uruguay 7
AZ - Azerbaigian 6
HN - Honduras 6
PS - Palestinian Territory 6
BG - Bulgaria 5
BY - Bielorussia 5
GR - Grecia 5
MD - Moldavia 5
PT - Portogallo 5
RS - Serbia 5
AM - Armenia 4
BO - Bolivia 4
CI - Costa d'Avorio 4
EU - Europa 4
SN - Senegal 4
BA - Bosnia-Erzegovina 3
BE - Belgio 3
GN - Guinea 3
HU - Ungheria 3
LB - Libano 3
MK - Macedonia 3
NG - Nigeria 3
NI - Nicaragua 3
OM - Oman 3
SI - Slovenia 3
TH - Thailandia 3
BF - Burkina Faso 2
BN - Brunei Darussalam 2
BZ - Belize 2
CG - Congo 2
CY - Cipro 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GP - Guadalupe 2
GT - Guatemala 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
Totale 27.163
Città #
Hong Kong 6.840
Ann Arbor 2.093
Woodbridge 1.132
Singapore 1.042
San Jose 814
Chandler 699
Jacksonville 666
Princeton 627
Ashburn 588
Houston 551
Dallas 541
Wilmington 395
Dong Ket 326
The Dalles 283
Council Bluffs 261
Izmir 223
Dublin 209
Lauterbourg 197
Beijing 181
Ho Chi Minh City 174
Andover 147
Nanjing 133
Boardman 116
Moscow 106
Pellezzano 103
Hanoi 99
Los Angeles 99
New York 95
Munich 79
Memphis 71
Naples 68
São Paulo 64
Santa Clara 63
Nuremberg 61
Washington 58
Salerno 55
Düsseldorf 50
Shenyang 49
Fairfield 46
Changsha 45
Columbus 43
Hebei 42
Buenos Aires 41
Norwalk 40
Jiaxing 38
Nanchang 37
Redwood City 37
Tokyo 29
Haiphong 28
Baghdad 27
Dearborn 27
Rio de Janeiro 27
Orem 26
Rome 26
Chicago 25
Milan 25
Montreal 25
Tianjin 25
Da Nang 24
Brooklyn 23
Frankfurt am Main 22
Lappeenranta 22
Turku 22
Warsaw 22
Boston 20
Seattle 20
London 19
Poplar 19
Mestre 18
Johannesburg 17
Quito 17
Atlanta 16
Belo Horizonte 16
Denver 16
Phoenix 16
Pune 16
Mexico City 15
Vienna 15
Curitiba 14
Seoul 14
Shanghai 14
Stockholm 14
Amman 13
Asunción 13
Buffalo 13
Chennai 13
Dhaka 13
Charlotte 12
Toronto 12
Brasília 11
Cambridge 11
Nairobi 11
Raleigh 11
San Diego 11
San Francisco 11
Tashkent 11
Biên Hòa 10
Hải Dương 10
Istanbul 10
Latina 10
Totale 20.654
Nome #
Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project) 957
La triptasi sierica nella diagnosi di mastocitosi sistemica in pazienti adulti senza lesioni cutanee 656
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study 588
Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control 566
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice 517
Fragments of truth: T-cell targets of polyclonal immunoglobulins in autoimmune diseases 500
Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema 388
Control of arachidonate levels within inflammatory cells. 375
A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy 361
Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: Data from the Campania Rare Disease Registry 356
Anaphylaxis and cardiovascular diseases 325
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma 314
Integrated care pathways for airway diseases (AIRWAYS-ICPs) 278
KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis 275
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT 274
Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis 233
Multidisciplinary challenges inmastocytosis and how to address with personalizedmedicine approaches 225
Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology 214
Diagnostic and therapeutic management of hereditary angioedema due to C1-inhibitor deficiency: The Italian experience 211
Characterization of platelet-activating factor synthesized by normal and granulocyte-macrophage colony-stimulating factor-primed human eosinophils. 208
A review of hereditary angioedema and recombinant human C1-inhibitor treatment 208
A randomised, placebo-controlled, double blind phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema 203
Heterogeneity of human Fc epsilon RI-bearing cells. 199
Allergia alimentare e probiotici: nuovi aspetti sulle interazioni tra il sistema immunitario ed i batteri commensali intestinali 183
Antigen-induced generation of lyso-phospholipids in human airways. 179
Secretory phospholipases A2 activate selective functions in human eosinophils 175
Stress and Psychological Factors in the Variable Clinical Phenotype of Hereditary Angioedema in Children: A Pilot Study 172
Arachidonic acid metabolism during antigen and ionophore activation of the mouse bone marrow derived mast cell. 167
Activation of human basophils by staphylococcal protein A. I. The role of cyclic AMP, arachidonic acid metabolites, microtubules and microfilaments. 163
Activation of human inflammatory cells by secreted phospholipases A2 158
Current concepts on diagnosis and treatment of mastocytosis. 155
Advances in the classification and treatment of mastocytosis: Current status and outlook toward the future 155
Activation of cytokine production by secreted phospholipase A2 in human lung macrophages expressing the M-type receptor 154
Molecular and cellular biology of mast cells and basophils. 151
Antileucotrieni nell'asma bronchiale: bilancio e prospettive 151
AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation 150
ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle 149
A unique case of angioedema with anti-C1 inhibitor antibodies and normal C1 inhibitor levels 143
Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC 138
Non lymphomatous clonal B-Cell populations in enlarged lymph nodes in acquired immunodeficiency syndrome. 138
Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases 137
MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis 134
L'acido ialuronico nella regolazione delle risposte infiammatorie ed immunologiche 132
Editorial overview: Immunomodulation: Modulation of the immune system: Per aspera ad astra 132
Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group 130
Biochemical functions of a pool of arachidonic acid associated with triglycerides in human inflammatory cells. 129
A Survey of Clinical Features of Allergic Rhinitis in Adults 128
Assay of antibody to group A streptococcal carbohydrate by enzyme-linked immunosorbent assay. 127
Human Macrophages and Monocytes Express Functional Na+/Ca2+ Exchangers 1 and 3Sodium Calcium Exchange: A Growing Spectrum of Pathophysiological Implications 126
Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study 124
Biological effects of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine in the human neutrophil. 124
Home Therapy with Plasma-Derived C1 Inhibitor: A Strategy to Improve Clinical Outcomes and Costs in Hereditary Angioedema 124
Pharmacological modulation of human mast cells and basophils 124
Elevated plasma levels of vascular permeability factors in C1 inhibitor-deficient hereditary angioedema 123
Benzene metabolites inhibit the release of proinflammatory mediators and cytokines from human basophils 122
Biomarkers for evaluation of mast cell and basophil activation 122
Are mast cells MASTers in HIV-1 infection? 121
Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions 120
Molecular diagnosis and the Italian Board for ISAC. 119
Mast cells as effector cells of innate immunity and regulators of adaptive immunity 118
Research needs in allergy: an EAACI position paper, in collaboration with EFA 117
360 degree perspective on allergic rhinitis management in Italy: A survey of GPs, pharmacists and patients 117
Evaluation of vaccination safety in children with mastocytosis 117
Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement 117
Relative amounts of 1-O-alkyl- and 1-acyl-2-acetyl-sn-glycero-3-phosphocholine in stimulated endothelial cells. 115
Short-term and long-term role of platelet activating factor as a mediator of in vivo platelet aggregation. 115
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal 115
Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes. 114
What we should learn from the London Olympics 114
Arachidonic acid remodeling in human inflammatory cells migrating to the lung in vivo. 113
Migration of human inflammatory cells into the lung results in the remodeling of arachidonic acid into a triglyceride pool. 111
Inhibition of IgE-mediated release of histamine and peptide leukotriene from human basophils and mast cells by forskolin. 111
Perioperative anaphylactic risk score for risk-oriented premedication. 111
HIV-1 envelope gp41 peptides promote migration of human FcεRI+ cells and inhibit IL-13 synthesis through interaction with formyl peptide receptors 111
Evidence that increasing the cellular content of eicosapentaenoic acid does not reduce the biosynthesis of platelet-activating factor. 109
European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives 109
Expression and function of angiopoietins and their tie receptors in human basophils and mast cells 109
Role of human mast cells and basophils in bronchial asthma. 108
Oxidative stress markers are increased in patients with mastocytosis 107
Inhibition of histamine and prostaglandin D2 release from human lung mast cells by ciclosporin A. 107
Factors that influence the proportions of platelet-activating factor and 1-acyl-2-acetyl-sn-glycero-3-phosphocholine synthesized by the mast cell. 107
Differential roles for triglyceride and phospholipid pools of arachidonic acid in human lung macrophages. 107
Sensitization to Common and Uncommon Pets or Other Furry Animals: Which May Be Common Mechanisms? 107
Role of human FcεRI+ cells in HIV-1 infection 107
Management of chronic spontaneous urticaria: practical parameters 106
ARIA Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology 106
Mutational Spectrum of the C1 Inhibitor Gene in a Cohort of Italian Patients with Hereditary Angioedema: Description of Nine Novel Mutations 105
Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis 105
Simplexide Induces CD1d-Dependent Cytokine and Chemokine Production from Human Monocytes 104
Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. 104
Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: An expert opinion 104
Phenotypical and functional heterogeneity of human lung macrophages 103
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 103
Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; The American Academy of Allergy, Asthma & Immunology; And the European Academy of Allergology and Clinical Immunology 102
Bone Marrow Failure Syndromes, Overlapping Diseases with a Common Cytokine Signature 102
Mastocytosis presenting as cardiac emergency 102
Influence of immunologic activation and cellular fatty acid levels on the catabolism of platelet-activating factor within the murine mast cell (PT-18). 101
Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study. 100
Recent advances in our understanding of the biochemical interactions between platelet-activating factor and arachidonic acid. 100
Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor. 100
Totale 17.950
Categoria #
all - tutte 86.277
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.277


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021353 0 0 0 0 0 0 0 0 0 0 0 353
2021/20221.047 9 3 4 18 10 19 9 44 166 139 137 489
2022/20231.740 184 104 59 200 244 388 12 165 260 6 93 25
2023/20241.002 82 110 122 49 97 174 23 44 11 40 47 203
2024/20252.428 79 34 33 96 109 283 353 246 465 199 281 250
2025/202614.113 1.342 3.676 3.071 568 1.025 558 1.660 361 410 867 361 214
Totale 27.511